Healthcare provider profile · identity verified

Sajid Hussain, MD

Psychiatry · BATTLE CREEK, MI · NPI 1073545133

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Clonazepam	Clonazepam	370	56
Quetiapine Fumarate	Quetiapine Fumarate	309	54
Trazodone Hcl	Trazodone Hcl	307	56
Lorazepam	Lorazepam	253	46
Benztropine Mesylate	Benztropine Mesylate	252	36
Clonidine Hcl	Clonidine Hcl	228	18
Divalproex Sodium Er	Divalproex Sodium	219	28
Lamotrigine	Lamotrigine	210	37
Olanzapine	Olanzapine	208	26
Risperidone	Risperidone	207	29
Aripiprazole	Aripiprazole	194	32
Fluoxetine Hcl	Fluoxetine Hcl	189	29
Haloperidol	Haloperidol	181	11
Sertraline Hcl	Sertraline Hcl	155	29
Divalproex Sodium	Divalproex Sodium	144	19
Clozapine	Clozapine	143	17
Ziprasidone Hcl	Ziprasidone Hcl	122	18
Oxcarbazepine	Oxcarbazepine	120	suppressed
Propranolol Hcl	Propranolol Hcl	120	21
Bupropion Xl	Bupropion Hcl	89	11
Duloxetine Hcl	Duloxetine Hcl	85	17
Escitalopram Oxalate	Escitalopram Oxalate	84	18
Invega Sustenna	Paliperidone Palmitate	83	16
Prazosin Hcl	Prazosin Hcl	79	19
Alprazolam	Alprazolam	75	19
Lithium Carbonate	Lithium Carbonate	71	suppressed
Paliperidone Er	Paliperidone	70	12
Buspirone Hcl	Buspirone Hcl	68	17
Gabapentin	Gabapentin	68	13
Mirtazapine	Mirtazapine	67	12
Zolpidem Tartrate	Zolpidem Tartrate	61	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	59	suppressed
Citalopram Hbr	Citalopram Hydrobromide	56	12
Hydroxyzine Pamoate	Hydroxyzine Pamoate	56	14
Diazepam	Diazepam	52	suppressed
Guanfacine Hcl Er	Guanfacine Hcl	52	suppressed
Lurasidone Hcl	Lurasidone Hcl	51	12
Hydroxyzine Hcl	Hydroxyzine Hcl	50	11
Topiramate	Topiramate	50	13
Venlafaxine Hcl Er	Venlafaxine Hcl	49	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	45	suppressed
Carbamazepine Er	Carbamazepine	39	suppressed
Omeprazole	Omeprazole	38	suppressed
Carbamazepine	Carbamazepine	35	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	35	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	34	suppressed
Risperdal Consta	Risperidone Microspheres	34	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	33	suppressed
Desmopressin Acetate	Desmopressin Acetate	31	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	27	suppressed
Trintellix	Vortioxetine Hydrobromide	27	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	26	suppressed
Perphenazine	Perphenazine	24	suppressed
Vraylar	Cariprazine Hcl	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Atenolol	Atenolol	22	suppressed
Aristada	Aripiprazole Lauroxil	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Bupropion Hcl	Bupropion Hcl	20	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	20	suppressed
Lithium Carbonate Er	Lithium Carbonate	20	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	19	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Suboxone	Buprenorphine Hcl/Naloxone Hcl	16	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	16	suppressed
Rexulti	Brexpiprazole	15	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	14	suppressed
Doxepin Hcl	Doxepin Hcl	14	suppressed
Metformin Hcl	Metformin Hcl	14	suppressed
Thiothixene	Thiothixene	14	suppressed
Invega Trinza	Paliperidone Palmitate	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	13	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	13	suppressed
Zonisamide	Zonisamide	13	suppressed
Eszopiclone	Eszopiclone	12	suppressed
Olanzapine Odt	Olanzapine	12	suppressed
Vilazodone Hcl	Vilazodone Hcl	12	suppressed
Vivitrol	Naltrexone Microspheres	12	suppressed
Folic Acid	Folic Acid	11	suppressed
Imipramine Hcl	Imipramine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error